Thrombopoietin levels in Quebec platelet disorderImplications for the mechanism of thrombocytopenia
Thrombopoietin (TPO) is the primary regulator of platelet production.
1,2 TPO levels in plasma are increased in disorders that impair megakaryocyte and platelet production, such as aplastic anemia, and are normal in thrombocytopenic disorders that do not reduce the megakaryocyte mass, including those that accelerate platelet clearance. 1, 2 We postulated that a detailed analysis of TPO levels in Quebec platelet disorder (QPD) might provide insights into why platelet counts are reduced in this inherited bleeding disorder 3 which is caused by a duplication mutation of PLAU, the urokinase plasminogen activator (uPA) gene. 4, 5 QPD markedly and selectively increases the production of normal PLAU transcripts by the disease chromosome in megakaryocytes but not in leukocytes through unknown mechanisms, 6 and this increases megakaryocyte and platelet uPA levels by more than 100-fold. 7, 8 As QPD megakaryocytes and platelets sequester uPA in α-granules, 8 the disorder results in a unique, platelet activation-dependent, gain-of-function defect in fibrinolysis, without systemic fibrinolysis. 9 In QPD, platelet morphology (by light and electron microscopy), size, 3 and dense granule release are normal, and secondary platelet aggregation is absent with epinephrine, with or without reduced maximal aggregation with collagen, adenosine diphosphate, and/or thromboxane analog U46619. 10 Many persons with QPD have thrombocytopenia as platelet counts in this disorder are typically about 50% lower than the platelet counts of unaffected relatives (reported range: ~120-245 × 10 9 /L 11 ). The reduction in platelet counts in QPD is clinically significant as lower platelet counts are associated with wound healing problems.
11
To gain insights into the reduced platelet counts in QPD, we evaluated TPO levels and platelet counts with the approval of the Hamilton
Integrated Research Ethics Board and the Research Ethics Board of
Centre Hospitalier Universitaire Sainte-Justine and written informed consent of blood donors. Platelet-poor plasma for TPO analyses was prepared using EDTA-anticoagulated blood (collected using vacutainers) from QPD (n = 7 representative individuals with the QPD genetic mutation who had often donated samples for research [4] [5] [6] [7] [8] [9] [10] [11] ) and general population control participants (n = 12). Plasmas were tested using The reasons for thrombocytopenia in QPD could be complex.
TPO cleavage by uPA increases its activity, whereas TPO cleavage by plasmin has the opposite effect. 12 As TPO levels in QPD plasma were <31.3 pg/mL, we were unable to investigate whether QPD causes increased TPO proteolysis. The sequestration of uPA in QPD α-granules (which prevents systemic fibrinolysis) 9 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
